Antigenic
CD4+ T Cell
Marburg Virus
Non-mutagenic
Non-toxic and High world population coverage
Peptide based vaccine
Journal
Journal of King Saud University. Science
ISSN: 2213-686X
Titre abrégé: J King Saud Univ Sci
Pays: Saudi Arabia
ID NLM: 9886378
Informations de publication
Date de publication:
Feb 2022
Feb 2022
Historique:
medline:
1
2
2022
pubmed:
1
2
2022
entrez:
17
6
2024
Statut:
ppublish
Résumé
Marburg, a RNA virus (MRV), is responsible for causing hemorrhagic fever that affects humans and non-human primates. World Health Organization (WHO), National Institutes of Health (NIH) and Centre of Disease Control and Prevention (CDC) considered this as an extremely dangerous virus, thus categorised as risk group 4, category A priority pathogen and category "A" bioterrorism agent, respectively. Despite of all these alarming concerns, no prophylaxis arrangements are available against this virus till date. In fact, the construction of immunogenic vaccine candidates by traditional molecular immunology methods is time consuming and very expensive. Considering these concerns, herein, we have designed CD4 + T Cell multiepitopes against MRV using
Identifiants
pubmed: 38881729
doi: 10.1016/j.jksus.2021.101751
pmc: PMC11178283
pii:
doi:
Types de publication
Journal Article
Langues
eng
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.